Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test

https://doi.org/10.1016/j.pbb.2003.12.019Get rights and content

Abstract

In spite of the addictive properties of cannabinoids, under certain circumstances, they can evoke strong anxiogenic and aversive responses in humans and in animal tests of anxiety. Effects of different doses of CP 55,940 (10, 20, and 40 μg/kg) were tested in the low-light, familiar (LF) apparatus test condition of the social interaction test. The 40-μg/kg dose of CP 55,940 significantly decreased the time spent in social interaction, indicating an anxiogenic effect. This dose also had an independent effect of reducing locomotor activity. In rats tested undrugged 24 h after testing with 40 μg/kg, there was a significant anxiogenic effect, indicating conditioned anxiety. The group of rats injected with 40 μg/kg immediately after the social interaction test showed an unexpected significant anxiolytic effect when tested undrugged 24 h later. In an additional experiment, rats were tested in the high-light, familiar (HF) apparatus test condition after 10 or 40 μg/kg, and only those that were tested after 40 μg/kg showed an anxiogenic effect on the test day and a conditioned anxiogenic effect when tested undrugged 24 h later. Once again, those injected with 40 μg/kg after the social interaction test displayed an anxiolytic effect when tested undrugged 24 h later. We provide the first evidence for unconditioned and conditioned anxiogenic-like responses to a cannabinoid agonist in the social interaction test.

Introduction

The motivation to use marijuana is thought to lie in part on its ability to assuage symptoms of anxiety (Porter and Felder, 2001), but cannabis users report feelings of anxiety and panic reactions Hall et al., 1994, Hall and Solowij, 1998 in equal measure to those of relaxation and euphoria (Hall et al., 1994). It is possible that the reasons for this lie in bidirectional effects of cannabinoids on anxiety, with low doses having anxiolytic effects and high doses having anxiogenic ones. The data from animal tests provide further evidence of bidirectional modulation of anxiety by the cannabinoid system. Low doses of the cannabinoid receptor agonists, nabilone (Onaivi et al., 1990), CP 55,940 Genn et al., 2003, Marco et al., 2004, and Δ9-tetrahydrocannabinol (THC) (Berrendero and Maldonado, 2002), induced anxiolytic effects in the elevated plus maze and light–dark crossing tests. In contrast, high doses of the cannabinoid agonist HU-210 produced anxiogenic responses in the defensive withdrawal test (Rodriguez de Fonseca et al., 1996) and enhanced emotional responding to tactile stimulation (Giuliani et al., 2000), whereas mid-high doses of CP 55,940 had anxiogenic effects in the plus maze Arévalo et al., 2001, Marı́n et al., 2003, Marco et al., 2004.

The cannabinoid receptor agonist CP 55,940 binds to the brain cannabinoid CB1 receptor with high affinity (Herkenham et al., 1991) and has been shown to be approximately 30 times more potent than THC (Little et al., 1988). However, not all the behavioural effects of CP 55,940 seem to be mediated by the CB1 receptor inasmuch as the reduction in directed exploration in the holeboard and the anxiogenic effect in the plus maze were not reversed by the CB1 receptor antagonist SR 141716A Arévalo et al., 2001, Romero et al., 2002. It has recently been suggested that there is a role for a novel cannabinoid receptor in the mediation of anxiety (Haller et al., 2002) inasmuch as both wild type and CB1 knockout mice show changes in anxiety in the plus maze in response to the functional CB1 receptor antagonist SR141716A. This antagonist binds to the putative novel cannabinoid-sensitive receptor (Haller et al., 2002), which constitutes a candidate for the mediation of preserved effects of cannabinoids in CB1 knockout mice Jarai et al., 1999, Zimmer et al., 1999, Di Marzo et al., 2000, Breivogel et al., 2001, Hajos et al., 2001. It is therefore possible that different cannabinoid receptors may mediate anxiety in different ways. Evidence for an endogenous anxiolytic cannabinoid tone comes from the intrinsic effects of the receptor antagonist SR141716A. This drug has anxiogenic effects in the defensive withdrawal and elevated plus maze tests in rats Navarro et al., 1997, Arévalo et al., 2001.

The anxiogenic effects of abused drugs may constitute salient stimuli to which drug-associated negative symptoms are classically conditioned. For example, the phenomenon of test-specific conditioned anxiety to an anxiogenic dose of nicotine has been demonstrated in both the social interaction and the elevated plus maze tests File et al., 2002, Tucci et al., 2002. Other drugs of abuse, such as cocaine (DeVries and Pert, 1998), produce a similar pattern of conditioned anxiety, and this phenomenon has been closely linked to cocaine's abuse potential Goeders, 1997, Goeders, 2002.

The purpose of the present experiment was to explore the possible bidirectional effects of CP 55,940 on anxiety in the social interaction test File, 1992, File and Seth, 2003, as well as whether anxiety could be conditioned to a mid-high dose of the drug. In the social interaction test, which models generalised anxiety disorder, the dependent variable is the time spent in social interaction by pairs of rats, and the anxiety generated by this test can be manipulated by changing the light level and/or the rats' familiarity within the test arena. The greatest level of anxiety is generated when rats are tested in an unfamiliar test arena that is lit by high light [high-light unfamiliar (HU) test condition]. A moderate level of anxiety is generated by testing rats in an arena with which they have been familiarised, but which is lit by high light [high-light familiar (HF) test condition]. The lowest level of anxiety is generated by testing rats in a familiar arena, lit by low light [low-light, familiar (LF) test condition]. Increases in social interaction are indicative of an anxiolytic effect, and decreases indicate an anxiogenic response. To test for possible anxiolytic effects, we used the HU and HF test conditions inasmuch as these conditions generate low levels of social interaction in the control group and are most sensitive to the effects of anxiolytics File and Hyde, 1978, File, 1980, File and Seth, 2003. To test for possible anxiogenic effects, we used the LF test condition, which generates the highest level of social interaction and is most sensitive to anxiogenic drug effects (e.g., File et al., 1982, File et al., 1988). Conditioned anxiogenic effects were explored in both the LF and HF test conditions.

Section snippets

Animals

Male hooded Lister rats (Charles River, Margate, Kent, UK) weighing 220–250 g were housed singly in 45×28×20-cm-high cages for 7 days prior to the start of behavioural testing. All the cages were in racks that allowed the rats to see, hear, and smell other rats. Food and water were freely available to all the animals. The room in which animals were housed was lit with dim light and maintained at 22 °C. Lights were on from 0700–1900 h. The experimental procedures carried out in this study were

Experiment 1: effects of low doses of CP 55,940 in the HU and HF test conditions

The split-plot ANOVA revealed that there were no effects of drug on the time spent in social interaction or on locomotor activity [F(3,28)<1.0, n.s. in both cases; see Table 1]. Neither were there significant Drug×Familiarity interactions under these conditions on either social interaction [F(3,28)=0.6, n.s.] or locomotor activity [F(3,28)=2.6, n.s.]. However, there were significant effects of familiarity to increase both social interaction [F(1,28)=8.3, P<.01] and locomotor activity [F

Discussion

We found no evidence for an anxiolytic effect in the social interaction test following low doses of CP 55,940. Thus, the effects in this test differ from those seen in the elevated plus maze, in which anxiolytic effects have been seen Genn et al., 2003, Marco et al., 2004. There is evidence from factor analysis studies that the two tests measure different states of anxiety (File, 1992) and considerable evidence that they are mediated by different neurobiological pathways Cheeta et al., 2000,

Acknowledgments

This study was supported in part by a grant from the CONICIT-ULA, Venezuela.

References (46)

  • S.E. File et al.

    Neurobiological mechanisms by which nicotine mediates different types of anxiety

    Eur. J. Pharmacol.

    (2000)
  • N.E. Goeders

    A neuroendocrine role in cocaine reinforcement

    Psychoneuroendocrinology

    (1997)
  • N.E. Goeders

    The HPA axis and cocaine reinforcement

    Psychoneuroendocrinology

    (2002)
  • N. Hajos et al.

    Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus

    Neuroscience

    (2001)
  • W. Hall et al.

    Adverse effects of cannabis

    Lancet

    (1998)
  • M. Lepore et al.

    Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward

    Life Sci.

    (1995)
  • I.S. McGregor et al.

    Aversive effects of the synthetic cannabinoid CP 55,940 in rats

    Pharmacol. Biochem. Behav.

    (1996)
  • A.C. Porter et al.

    The endocannabinoid nervous system: unique opportunities for therapeutic intervention

    Pharmacol. Ther.

    (2001)
  • E.M. Romero et al.

    Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats

    Dev. Brain Res.

    (2002)
  • F. Berrendero et al.

    Involvement of the opioid system in the anxiolytic-like effects induced by delta (9)-tetrahydrocannabinol

    Psychopharmacology

    (2002)
  • C.S. Breivogel et al.

    Evidence for a new G protein-coupled cannabinoid receptor in mouse brain

    Mol. Pharmacol.

    (2001)
  • A.C. DeVries et al.

    Conditioned increases in anxiogenic-like behavior following exposure to contextual stimuli associated with cocaine are mediated by corticotropin-releasing factor

    Psychopharmacology

    (1998)
  • V. Di Marzo et al.

    Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice: evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in mouse brain

    J. Neurochem.

    (2000)
  • Cited by (0)

    View full text